Evrofarma SA
ASE:EVROF.AT
0.955 (EUR) • At close November 16, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 45.719 | 48.761 | 45.381 | 36.699 | 33.909 | 33.48 | 32.985 | 30.986 | 28.906 | 29.646 | 25.272 | 23.467 |
| Cost of Revenue
| 37.066 | 41.702 | 39.801 | 32.86 | 29.175 | 27.505 | 26.952 | 25.691 | 23.789 | 23.015 | 19.188 | 19.309 |
| Gross Profit
| 8.653 | 7.059 | 5.58 | 3.839 | 4.734 | 5.975 | 6.033 | 5.295 | 5.117 | 6.631 | 6.084 | 4.158 |
| Gross Profit Ratio
| 0.189 | 0.145 | 0.123 | 0.105 | 0.14 | 0.178 | 0.183 | 0.171 | 0.177 | 0.224 | 0.241 | 0.177 |
| Reseach & Development Expenses
| 0 | 0.16 | 0.357 | 0.459 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 1.247 | 1.376 | 1.117 | 1.035 | 0.9 | 0.926 | 0.972 | 1.229 | 1.083 | 1.527 | 1.625 |
| Selling & Marketing Expenses
| 0 | 3.392 | 3.309 | 3.609 | 3.611 | 3.794 | 3.527 | 2.926 | 3.063 | 2.611 | 3.647 | 2.568 |
| SG&A
| 5.848 | 4.639 | 4.265 | 4.726 | 4.23 | 4.381 | 4.156 | 3.587 | 3.9 | 4.342 | 5.174 | 4.193 |
| Other Expenses
| 0 | 0 | 0.036 | 0 | 0.09 | 0 | 0 | 0 | -0.007 | 0 | 0 | 0 |
| Operating Expenses
| 5.848 | 3.032 | 4.229 | 3.319 | 4.14 | 4.381 | 4.156 | 3.587 | 3.907 | 4.342 | 5.174 | 3.605 |
| Operating Income
| 2.805 | 3.655 | 1.351 | 0.231 | 0.594 | 1.594 | 1.877 | 1.708 | 1.21 | 2.289 | 0.91 | 0.826 |
| Operating Income Ratio
| 0.061 | 0.075 | 0.03 | 0.006 | 0.018 | 0.048 | 0.057 | 0.055 | 0.042 | 0.077 | 0.036 | 0.035 |
| Total Other Income Expenses Net
| 0.083 | -0.948 | -0.756 | -0.491 | -0.287 | -1.267 | -0.616 | -0.597 | -0.303 | -1.136 | -1.237 | -1.425 |
| Income Before Tax
| 2.888 | 2.707 | 1.5 | -0.26 | 1.189 | 0.327 | 1.261 | 1.111 | 0.907 | 1.153 | 0.268 | -0.599 |
| Income Before Tax Ratio
| 0.063 | 0.056 | 0.033 | -0.007 | 0.035 | 0.01 | 0.038 | 0.036 | 0.031 | 0.039 | 0.011 | -0.026 |
| Income Tax Expense
| 0.608 | 0.505 | 0.103 | 0.095 | 0.115 | 0.169 | 0.282 | 0.575 | 0.495 | 0.626 | 0.548 | 0.201 |
| Net Income
| 2.28 | 2.202 | 1.419 | -0.355 | 1.08 | 0.157 | 0.979 | 0.536 | 0.412 | 0.527 | -0.28 | -0.398 |
| Net Income Ratio
| 0.05 | 0.045 | 0.031 | -0.01 | 0.032 | 0.005 | 0.03 | 0.017 | 0.014 | 0.018 | -0.011 | -0.017 |
| EPS
| 0.17 | 0.16 | 0.1 | -0.026 | 0.079 | 0.012 | 0.072 | 0.039 | 0.03 | 0.039 | -0.021 | -0.029 |
| EPS Diluted
| 0.17 | 0.16 | 0.1 | -0.026 | 0.079 | 0.012 | 0.072 | 0.039 | 0.03 | 0.039 | -0.021 | -0.029 |
| EBITDA
| 5.907 | 5.748 | 3.957 | 1.634 | 3.426 | 2.522 | 3.493 | 3.438 | 3.907 | 3.846 | 3.436 | 3.21 |
| EBITDA Ratio
| 0.129 | 0.118 | 0.087 | 0.045 | 0.101 | 0.075 | 0.106 | 0.111 | 0.135 | 0.13 | 0.136 | 0.137 |